# Parnax Lab (NSE: PARNAXLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/PARNAXLAB · Pivot · prices to 21 Oct 2026

Parnax Lab (NSE: PARNAXLAB) closed at ₹104.00 on 21 Oct 2026. With a market capitalisation of ₹119 Cr, it ranks 2568th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 10.1× trailing earnings, against a return on equity of 12.4% in FY26. Its 52-week range is ₹102.00 (21 Oct 2026) to ₹149.50 (10 Sep 2026); the last close is 30.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹70 Cr (+42.0% year on year) and net profit ₹2 Cr (−25.6%), on a consolidated basis. Promoters held 72.30% of the company as of 30 Jun 2026; 9.41% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹104.00 |
| Market cap | ₹119 Cr |
| P/E (trailing) | 10.1 |
| ROE | 12.4% (FY26) |
| ROCE | 17.4% (FY26) |
| Debt to equity | 0.78 |
| 52-week high | ₹149.50 (10 Sep 2026) |
| 52-week low | ₹102.00 (21 Oct 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹70 Cr | +42.0% | ₹2 Cr | −25.6% | ₹1.90 |
| Q3 FY26 | ₹63 Cr | +56.5% | ₹3 Cr | +124.8% | ₹2.37 |
| Q2 FY26 | ₹63 Cr | +29.4% | ₹4 Cr | +6.2% | ₹3.15 |
| Q1 FY26 | ₹53 Cr | +6.5% | ₹3 Cr | −18.0% | ₹2.85 |
| Q4 FY25 | ₹49 Cr | +5.8% | ₹3 Cr | +30.2% | ₹2.55 |
| Q3 FY25 | ₹40 Cr | −21.1% | ₹1 Cr | −44.5% | ₹1.06 |
| Q2 FY25 | ₹48 Cr | +13.5% | ₹3 Cr | +82.4% | ₹2.97 |
| Q1 FY25 | ₹50 Cr | +2.8% | ₹4 Cr | +19.8% | ₹3.47 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹188 Cr | ₹12 Cr |
| FY24 | ₹189 Cr | ₹10 Cr |
| FY23 | ₹168 Cr | ₹9 Cr |
| FY22 | ₹163 Cr | ₹8 Cr |
| FY21 | ₹90 Cr | −₹0 Cr |
| FY20 | ₹95 Cr | −₹3 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.30%
- Non-institutions: 27.70%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Aspira Pathlab](https://app.pivotnow.in/stock/ASPIRA) | — | ₹125 Cr | — | — |
| [Krebs Biochemicals and Industries](https://app.pivotnow.in/stock/KREBSBIO) | ₹56.59 | ₹122 Cr | — | — |
| [Godavari Drugs](https://app.pivotnow.in/stock/GODAVARI) | — | ₹120 Cr | — | — |
| [Makers Labs](https://app.pivotnow.in/stock/MAKERSL) | ₹191.02 | ₹113 Cr | 48 | — |
| [Pharmaids Pharm](https://app.pivotnow.in/stock/PHARMAID) | — | ₹113 Cr | — | — |
| [BALAXI PHARMACEUTICALS](https://app.pivotnow.in/stock/BALAXI) | ₹20.31 | ₹112 Cr | 78.1 | — |

## Questions and answers

### What is the share price of Parnax Lab today?

Parnax Lab (NSE: PARNAXLAB) last closed at ₹104.00 on 21 Oct 2026. Its 52-week high is ₹149.50 and its 52-week low is ₹102.00.

### What is the market cap of Parnax Lab?

Parnax Lab's market capitalisation is ₹119 Cr (₹119 Cr) at the 22 Oct 2026 close, ranking 2568th among the NSE companies Pivot tracks.

### What is the P/E ratio of Parnax Lab?

Parnax Lab trades at a trailing P/E of 10.1.

### What is the ROE and ROCE of Parnax Lab?

Return on equity was 12.4% in FY26 and return on capital employed was 17.4% in FY26 (consolidated figures).

### Is Parnax Lab a debt-free company?

No. Parnax Lab's debt-to-equity ratio was 0.78 in FY26, with total debt of ₹22 Cr.

### What were Parnax Lab's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Parnax Lab reported revenue of ₹70 Cr, +42.0% year on year, and net profit of ₹2 Cr, −25.6% year on year.

### What is the shareholding pattern of Parnax Lab?

As of 30 Jun 2026: promoters 72.30%, non-institutions 27.70%. 9.41% of promoter shares were pledged.

### Who are Parnax Lab's competitors?

The listed Pharma & Healthcare companies closest to Parnax Lab by market cap are Aspira Pathlab, Krebs Biochemicals and Industries, Godavari Drugs, Makers Labs, Pharmaids Pharm and BALAXI PHARMACEUTICALS.

### Is Parnax Lab a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Parnax Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PARNAXLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.